{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:18:02Z","timestamp":1772633882052,"version":"3.50.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-026-02860-2","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:16:01Z","timestamp":1769069761000},"page":"698-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-8441","authenticated-orcid":false,"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2860_CR1","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227\u201336.","journal-title":"Blood"},{"key":"2860_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11899-024-00739-6","volume":"19","author":"B Mora","year":"2024","unstructured":"Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, et al. Prognostic and predictive models in myelofibrosis. Curr Hematol Malig Rep. 2024;19:223\u201335.","journal-title":"Curr Hematol Malig Rep"},{"key":"2860_CR3","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00277-020-04055-w","volume":"99","author":"S Verstovsek","year":"2020","unstructured":"Verstovsek S, Yu J, Kish JK, Paranagama D, Kaufman J, Myerscough C, et al. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Ann Hematol. 2020;99:2555\u201364.","journal-title":"Ann Hematol"},{"key":"2860_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70072","volume":"9","author":"P Guglielmelli","year":"2025","unstructured":"Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Morrone L, Mora B, et al. Cytopenic overt primary myelofibrosis at presentation: analysis of outcomes in the prospective, real-world ERNEST-2 registry. Hemasphere. 2025;9:e70072.","journal-title":"Hemasphere"},{"key":"2860_CR5","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"2860_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280\u20136.","journal-title":"Ann Intern Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02860-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02860-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02860-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:38:02Z","timestamp":1772609882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02860-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2860"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02860-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., Kite Pharma and CStone Pharmaceuticals; Advisor to Antegene Biotech LLC, Medical Director and FFF Enterprises Inc.; Partner in AZACA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research was conducted in accordance with the World Medical Association Declaration of Helsinki. All subjects included in the Pavia-CSM database gave written informed consent approved by the IRCCS Policlinico S. Matteo Foundation Institutional Ethics Committee. The Ethics Committee of the Hospital also approved a written informed consent for patients to donate samples for molecular research (reference number 20110004143 of the 26.9.2011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}